Article Abstract

Bevacizumab in small cell lung cancer

Authors: Giandomenico Roviello, Navid Sobhani, Daniele Generali


The randomized phase III, open-label, multicenter clinical trial, based on 205 patients with extensive-disease (ED) of small-cell lung cancer (SCLC), evaluated the efficacy and the safety of humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), in combination with etoposide and cisplatin in first line chemotherapeutic treatment (1).